Breaking News Instant updates and real-time market news.

GILD

Gilead

$68.17

-2.01 (-2.86%)

07:38
12/10/18
12/10
07:38
12/10/18
07:38

Gilead landing Daniel O'Day is a positive, says Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young views the appointment of Daniel O'Day as a positive for Gilead Sciences. One of the biggest overhangs for Gilead has been around who would be the next CEO and what that might signal around the company's strategy,.Young tells investors in a research note. She would expect the market to view this appointment positively, "since it gives clarity around one of the most important questions around building a Gilead thesis." The company is appointing a leader that will focus on product pipeline diversification and commercial growth, Young contends. She keeps an Overweight rating on Gilead with an $88 price target.

GILD Gilead
$68.17

-2.01 (-2.86%)

12/02/18
PIPR
12/02/18
NO CHANGE
Target $12
PIPR
Overweight
Alpine Immune Sciences' ALPN-101 active in GvHD, CTA by YE18, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Alpine (ALPN) presented two posters at ASH on proprietary variable Immunoglobulin Domain technology. In vivo data at ASH showed single doses enhanced survival in GvHD models compared to Bristol Myer's (BMY) Nujolix, he notes, adding that a CTA for ALPN-101 by YE18 should enable healthy volunteer data and lead to a Phase II GvHD start next year. The analyst also points out that Alpine presented novel Transmembrane ImmuneModulatory Proteins that can be engineered into T cells to enhance response in immunosuppressive environments. Importantly these strategies differ from TIP technology partnered to Kite (GILD) and offer further partnering opportunity, Tenthoff contends. He reiterates an Overweight rating and $12 price target on Alpine's shares.
11/19/18
CANT
11/19/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro could be worth $89-$97 per share in buyout, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young believes Tesaro (TSRO) could be valued at $89-$97 per share in a takeout scenario. The stock closed Friday up 31%, or $8.37, to $34.96 after Bloomberg reported that the company was exploring a sale after receiving some interest. The press article could be a way of garnering interest for the company beyond potentially initial interest, Young tells investors in a research note. In the past, she thinks Tesaro has been a potential takeout interest from biopharmaceutical companies. Companies like Amgen (AMGN), Gilead (GILD), and Celgene (CELG) have cancer platforms that could add a PARP inhibitor and benefit from Tesaro's various immuno-oncology pipeline assets, Young writes. She reiterates an Overweight rating on Tesaro with a $68 price target.
10/31/18
MZHO
10/31/18
NO CHANGE
Target $94
MZHO
Buy
Mizuho says concerns over UnitedHealth program impact on Gilead seem unwarranted
Mizuho analyst Salim Syed blames UnitedHealth's (UNH) introduction of a new a program, called "My ScriptRewards," that will try to convince plan participants to take a cheaper HIV regimen in return for $500 in debit cards for the weakness in shares of Gilead (GILD). However, the analyst views the worries as unwarranted, noting that Cimduo is the "common thread" between all of the regimens that UnitedHealth's program calls out and it is an inferior drug to Gilead's Biktarvy. Biktarvy is the backbone of the number one recommended regimen according to HHS treatment guidelines, noted Syed, who keeps a Buy rating and $94 price target on Gilead shares.
10/31/18
EVER
10/31/18
NO CHANGE
EVER
Outperform
Gilead sales not at risk from UnitedHealth promotions, says Evercore ISI
Evercore ISI analyst Umer Raffat attributes the pullback today in shares of Gilead Sciences (GILD) to concerns over the company's HIV franchise given UnitedHealth's (UNH) promotions of cheaper alternatives. UnitedHealth (UNH) is offering a rewards plan to patients starting with HIV medications to help promote the use of lower priced drugs, Jefferies analyst Michael Yee pointed out earlier today in a research note. Raffat, however, does not see risk to Gilead's sales from the promotions. UnitedHealth's is proposing a switch to two separate tablets, which is not in the HIV guidelines today, says the analyst. He keeps an Outperform rating on Gilead shares, which are down 6% to $68.00 in afternoon trading.

TODAY'S FREE FLY STORIES

ENR

Energizer

$48.35

6.34 (15.09%)

08:48
11/14/19
11/14
08:48
11/14/19
08:48
Recommendations
Energizer analyst commentary  »

Energizer price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SNNA

Sienna Biopharmaceuticals

$0.16

-0.008 (-4.74%)

08:47
11/14/19
11/14
08:47
11/14/19
08:47
Hot Stocks
Sienna Biopharmaceuticals says Nasdaq panel grants request for continued listing »

Sienna Biopharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$99.69

-0.245 (-0.25%)

08:47
11/14/19
11/14
08:47
11/14/19
08:47
Conference/Events
Fortinet management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 18

    Nov

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

PRSP

Perspecta

$27.79

-0.18 (-0.64%)

08:46
11/14/19
11/14
08:46
11/14/19
08:46
Hot Stocks
Perspecta Labs wins $6.6M award on DARPA GAPS program »

Perspecta announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$101.00

0.99 (0.99%)

08:45
11/14/19
11/14
08:45
11/14/19
08:45
Hot Stocks
Sarepta announces collaboration, license agreement with StrideBio »

arepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XNET

Xunlei

$5.79

0.07 (1.22%)

, AMC

AMC Entertainment

$8.77

-0.51 (-5.50%)

08:45
11/14/19
11/14
08:45
11/14/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

XNET

Xunlei

$5.79

0.07 (1.22%)

AMC

AMC Entertainment

$8.77

-0.51 (-5.50%)

CGC

Canopy Growth

$18.52

-0.69 (-3.59%)

NLOK

NortonLifeLock

$24.57

0.36 (1.49%)

FB

Facebook

$193.20

-1.27 (-0.65%)

HGV

Hilton Grand Vacations

$35.24

-0.07 (-0.20%)

HEXO

Hexo

$1.99

-0.14 (-6.59%)

ADT

ADT Inc.

$8.36

0.66 (8.57%)

BUD

AB InBev

$79.37

0.28 (0.35%)

ABB

ABB

$21.93

0.11 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 19

    Nov

  • 27

    Feb

UBER

Uber

$26.70

(0.00%)

08:43
11/14/19
11/14
08:43
11/14/19
08:43
Upgrade
Uber rating change  »

Uber upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

WMT

Walmart

$121.06

1.93 (1.62%)

08:43
11/14/19
11/14
08:43
11/14/19
08:43
Recommendations
Walmart analyst commentary  »

Baird says positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

PUFXF

Agraflora Organics

$0.00

(0.00%)

08:41
11/14/19
11/14
08:41
11/14/19
08:41
Hot Stocks
Agraflora Organics introduces organic lip balm SKU into 200 Gateway Newstands »

AgraFlora Organics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REED

Reed's

$0.72

0.0221 (3.17%)

08:41
11/14/19
11/14
08:41
11/14/19
08:41
Recommendations
Reed's analyst commentary  »

Reed's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:40
11/14/19
11/14
08:40
11/14/19
08:40
General news
U.S. initial jobless claims jumped 14k to 225k in the week ended October 9 »

U.S. initial jobless…

08:40
11/14/19
11/14
08:40
11/14/19
08:40
General news
FX Action: The dollar »

FX Action: The dollar was…

FCN

FTI Consulting

$105.68

0.095 (0.09%)

08:39
11/14/19
11/14
08:39
11/14/19
08:39
Conference/Events
FTI Consulting management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

TIXC

Tix Corp

$0.00

(0.00%)

08:39
11/14/19
11/14
08:39
11/14/19
08:39
Earnings
Tix Corp reports Q3 EPS (6c) vs. (2c) last year »

Reports Q3 revenue $3.13M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$60.04

-0.08 (-0.13%)

08:39
11/14/19
11/14
08:39
11/14/19
08:39
Recommendations
NetApp analyst commentary  »

NetApp price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 12

    Dec

ENPH

Enphase Energy

$18.93

-0.195 (-1.02%)

08:38
11/14/19
11/14
08:38
11/14/19
08:38
Hot Stocks
Enphase Energy says Vision Solar leverages products for customer experience »

Enphase Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMP

Immutep

$1.77

-0.135 (-7.11%)

08:36
11/14/19
11/14
08:36
11/14/19
08:36
Hot Stocks
Immutep announces European patent grant for LAG525 antibody »

Immutep announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSO

CytoSorbents

$4.44

0.05 (1.14%)

08:36
11/14/19
11/14
08:36
11/14/19
08:36
Conference/Events
CytoSorbents management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CCMP

Cabot Microelectronics

$156.67

0.28 (0.18%)

08:36
11/14/19
11/14
08:36
11/14/19
08:36
Downgrade
Cabot Microelectronics rating change  »

Cabot Microelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

RMBL

RumbleON

$1.50

-0.83 (-35.62%)

08:35
11/14/19
11/14
08:35
11/14/19
08:35
Recommendations
RumbleON analyst commentary  »

RumbleON price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

LINC

Lincoln Educational

$1.90

(0.00%)

08:35
11/14/19
11/14
08:35
11/14/19
08:35
Earnings
Lincoln Educational sees FY19 revenue, student starts up 3%-5% »

Ex. Transitional segment.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

08:35
11/14/19
11/14
08:35
11/14/19
08:35
General news
U.S. PPI rose 0.4% in October, with the core rate up 0.3% »

U.S. PPI rose 0.4% in…

LINC

Lincoln Educational

$1.90

(0.00%)

08:34
11/14/19
11/14
08:34
11/14/19
08:34
Earnings
Lincoln Educational reports Q3 EPS 5c, one est. 9c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

AMPY

Amplify Energy

$6.22

-0.17 (-2.66%)

08:34
11/14/19
11/14
08:34
11/14/19
08:34
Initiation
Amplify Energy initiated  »

Amplify Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:34
11/14/19
11/14
08:34
11/14/19
08:34
General news
Jobless Claims data reported »

Week of 11/9 Jobless…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.